Orchestra BioMed Holdings Inc. (OBIO) - Total Assets
Based on the latest financial reports, Orchestra BioMed Holdings Inc. (OBIO) holds total assets worth $104.81 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See OBIO net asset value for net asset value and shareholders' equity analysis.
Orchestra BioMed Holdings Inc. - Total Assets Trend (2020–2024)
This chart illustrates how Orchestra BioMed Holdings Inc.'s total assets have evolved over time, based on quarterly financial data.
Orchestra BioMed Holdings Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Orchestra BioMed Holdings Inc.'s total assets of $104.81 Million consist of 90.8% current assets and 9.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 29.2% |
| Accounts Receivable | $92.00K | 0.1% |
| Inventory | $173.00K | 0.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Orchestra BioMed Holdings Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Orchestra BioMed Holdings Inc. stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Orchestra BioMed Holdings Inc.'s current assets represent 90.8% of total assets in 2024, a decrease from 95.2% in 2020.
- Cash Position: Cash and equivalents constituted 29.2% of total assets in 2024, down from 53.4% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 0.2% of total assets.
Orchestra BioMed Holdings Inc. Competitors by Total Assets
Key competitors of Orchestra BioMed Holdings Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Orchestra BioMed Holdings Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.73 | 4.23 | 12.00 |
| Quick Ratio | 4.72 | 4.21 | 12.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $77.11 Million | $52.34 Million | $1.92 Million |
Orchestra BioMed Holdings Inc. - Advanced Valuation Insights
This section examines the relationship between Orchestra BioMed Holdings Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.96 |
| Latest Market Cap to Assets Ratio | 2.84 |
| Asset Growth Rate (YoY) | -20.0% |
| Total Assets | $76.17 Million |
| Market Capitalization | $216.26 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Orchestra BioMed Holdings Inc.'s assets at a significant premium (2.84x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Orchestra BioMed Holdings Inc.'s assets decreased by 20.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Orchestra BioMed Holdings Inc. (2020–2024)
The table below shows the annual total assets of Orchestra BioMed Holdings Inc. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $76.17 Million | -20.00% |
| 2023-12-31 | $95.21 Million | -0.38% |
| 2022-12-31 | $95.57 Million | +606.53% |
| 2021-12-31 | $13.53 Million | -64.49% |
| 2020-12-31 | $38.09 Million | -- |
About Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develop… Read more